GSK241115P40000
- 6.79
- 0.000.00%
GlaxoSmithKline Newsroom
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
GSK's RSV Vaccine Approved for Japanese Patients in Their 50s
Arexvy Approval Expanded to Adults Aged 50-59 at Increased Risk of Severe RSV Disease in Japan
Optimism Over Global Healthcare Sector Rises: Jefferies
Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board With Appointments of World Class Veterans
CDC Warns Against a Spike in COVID, Flu Cases
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
The phase III study of glaxosmithkline (GSK.US) IBAT inhibitor for the treatment of PBC-related cholestatic pruritus was successful.
On November 19, glaxosmithkline (GSK.US) announced that the Phase III GLISTEN study has achieved positive results.
GSK Says Trial of Itch Treatment Linerixibat Meets Primary Endpoint
Statement: GSK Continues to Show Strong Leadership in Its Access to Medicines Index Ranking
Linerixibat Shows Positive Phase III Results in Cholestatic Pruritus (Relentless Itch) in Primary Biliary Cholangitis (PBC)
Us CDC Says Since April Confirmed Avian Influenza A(H5) Virus Infections In 52 People In US; Aware Of Human Case Of H5N1 Bird Flu Reported In Canada & Is In Communication With Public Health Agency Of Canada
Global Companies With at Least 50% U.S. Revenue Exposure as Trump Eyes Tariffs: BofA
Express News | Johnson & Johnson China initiates layoffs, prompting some foreign companies to reassess their business in China and deepen localization.
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer
GSK Target Cut to GBP13.50 From GBP17.00 by Deutsche Bank
GSK Cut to Hold From Buy by Deutsche Bank
Trending Stocks This Week as Wall Street Sells off Amid Fed Remarks
US Manufacturing Index Rises To 43, Highest Since 2020